ductal carcinoma in situ

With more evidence for clinical utility in the scientific literature, the company expects finalized Medicare coverage before the end of the year.

The firm's revenues were hit by currency translation and differences in the timing of test reimbursement compared with the previous year's quarter.

In a large DCIS cohort, researchers showed the ability of Oncotype DX score to assess recurrence risk in patients treated with breast conservation surgery.

NEW YORK (GenomeWeb) ─ Genomic Health reported after the close of the market Tuesday that its third quarter revenues were up five percent year over year, falling slightly short of the Wall Street consensus estimate.

This article has been corrected to note that Brad Cole is Genomic Health's CFO and COO.

NEW YORK (GenomeWeb News) – Saying that Genomic Health's growth could fall short of consensus expectations, financial services firm Raymond James today downgraded shares of the Redwood City, Calif.-based firm's stock to Underperform from Market Perform.

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market on Friday that the national Medicare contractor for the firm's Oncotype DX breast cancer test has expanded Medicare coverage for the test.

In support of expanded utility for its Oncotype DX test in guiding cancer therapy decision-making, Genomic Health announced new data this week demonstrating that the test can help predict patients' risk of loco-regional recurrence after receiving chemotherapy and hormonal therapy

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.